Paragon Capital Management LLC Purchases New Holdings in Celgene Co. (CELG)

Paragon Capital Management LLC purchased a new stake in Celgene Co. (NASDAQ:CELG) in the first quarter, HoldingsChannel.com reports. The fund purchased 600 shares of the biopharmaceutical company’s stock, valued at approximately $57,000.

Several other institutional investors and hedge funds also recently made changes to their positions in CELG. Dynamic Technology Lab Private Ltd purchased a new position in Celgene during the 3rd quarter valued at about $527,000. Mackenzie Financial Corp boosted its stake in shares of Celgene by 0.8% during the 3rd quarter. Mackenzie Financial Corp now owns 1,095,968 shares of the biopharmaceutical company’s stock worth $98,078,000 after purchasing an additional 9,113 shares during the last quarter. HPM Partners LLC boosted its stake in shares of Celgene by 62.8% during the 3rd quarter. HPM Partners LLC now owns 76,273 shares of the biopharmaceutical company’s stock worth $6,826,000 after purchasing an additional 29,424 shares during the last quarter. Smith Moore & CO. acquired a new stake in shares of Celgene during the 3rd quarter worth about $275,000. Finally, Farmhouse Investment Management LLC boosted its stake in shares of Celgene by 22.5% during the 3rd quarter. Farmhouse Investment Management LLC now owns 145,900 shares of the biopharmaceutical company’s stock worth $13,057,000 after purchasing an additional 26,800 shares during the last quarter. Institutional investors and hedge funds own 74.92% of the company’s stock.

In related news, Director James J. Loughlin sold 23,466 shares of the firm’s stock in a transaction that occurred on Thursday, February 7th. The shares were sold at an average price of $87.29, for a total value of $2,048,347.14. Following the transaction, the director now owns 62,102 shares in the company, valued at $5,420,883.58. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, Director Ernest Mario purchased 2,000 shares of the business’s stock in a transaction that occurred on Tuesday, February 12th. The stock was acquired at an average price of $89.99 per share, for a total transaction of $179,980.00. The disclosure for this purchase can be found here. Company insiders own 0.39% of the company’s stock.

Shares of CELG traded up $0.96 during mid-day trading on Monday, hitting $95.10. The company had a trading volume of 6,674,192 shares, compared to its average volume of 11,861,181. The company has a debt-to-equity ratio of 3.21, a quick ratio of 2.12 and a current ratio of 2.23. Celgene Co. has a 1-year low of $58.59 and a 1-year high of $95.30. The stock has a market capitalization of $66.18 billion, a PE ratio of 12.50, a P/E/G ratio of 0.43 and a beta of 1.71.

Celgene (NASDAQ:CELG) last posted its quarterly earnings results on Thursday, January 31st. The biopharmaceutical company reported $2.39 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $2.32 by $0.07. Celgene had a net margin of 26.48% and a return on equity of 114.66%. The firm had revenue of $4.04 billion for the quarter, compared to analyst estimates of $3.98 billion. During the same quarter last year, the firm posted $2.00 earnings per share. As a group, sell-side analysts expect that Celgene Co. will post 10.01 earnings per share for the current fiscal year.

Several research firms have issued reports on CELG. Mizuho set a $103.00 price target on shares of Celgene and gave the stock a “buy” rating in a research note on Friday, April 5th. Cantor Fitzgerald reaffirmed a “buy” rating and set a $100.00 price target on shares of Celgene in a research note on Thursday, January 3rd. Goldman Sachs Group raised shares of Celgene from a “sell” rating to a “neutral” rating and raised their price target for the stock from $71.00 to $88.00 in a research note on Thursday, January 3rd. Jefferies Financial Group cut shares of Celgene from a “buy” rating to a “hold” rating and set a $95.00 price target on the stock. in a research note on Friday, February 1st. Finally, William Blair cut shares of Celgene from an “outperform” rating to a “market perform” rating in a research note on Monday, April 1st. One investment analyst has rated the stock with a sell rating, eighteen have given a hold rating and nine have given a buy rating to the company’s stock. Celgene currently has a consensus rating of “Hold” and a consensus price target of $99.41.

TRADEMARK VIOLATION NOTICE: “Paragon Capital Management LLC Purchases New Holdings in Celgene Co. (CELG)” was first reported by WKRB News and is the property of of WKRB News. If you are viewing this article on another domain, it was stolen and reposted in violation of U.S. and international trademark and copyright laws. The correct version of this article can be viewed at https://www.wkrb13.com/2019/04/15/paragon-capital-management-llc-purchases-new-holdings-in-celgene-co-celg.html.

About Celgene

Celgene Corporation, a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of cancer and inflammatory diseases worldwide. It offers REVLIMID, an oral immunomodulatory drug for multiple myeloma (MM), myelodysplastic syndromes (MDS), and mantle cell lymphoma; POMALYST/IMNOVID to treat multiple myeloma; OTEZLA, a small-molecule inhibitor of phosphodiesterase 4 for psoriatic arthritis and psoriasis; and ABRAXANE to treat breast, non-small cell lung, pancreatic, and gastric cancers.

See Also: Trading Stocks – What are percentage gainers?

Want to see what other hedge funds are holding CELG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Celgene Co. (NASDAQ:CELG).

Institutional Ownership by Quarter for Celgene (NASDAQ:CELG)

Receive News & Ratings for Celgene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene and related companies with MarketBeat.com's FREE daily email newsletter.